CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The project aims to develop a recombinant human antibody targeting Complement component C5 for treating atypical Haemolytic Uraemic Syndrome (aHUS). Through preclinical studies, it seeks to evaluate the safety and efficacy of this potential orphan drug in addressing this serious condition.
The Complement System is implicated in the onset, maintenance and amplification of tissue damage in several inflammatory clinical conditions.
Haemolytic uraemic syndrome (HUS) is a systemic disease characterized by damage to endothelial cells and erythrocytes, thrombocytopenia, micro thrombosis and kidney failure.
During the last few years it has become evident that familial atypical HUS is strongly associated with mutations in proteins needed either for activation or regulation of the alternati…
ADIENNE S.r.l.
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Italy, Trieste
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE
United Kingdom, LONDON
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
France, EVREUX
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
